GLP1 News and Research

RSS

GLP-1 hormone can predict metabolic efficacy of gastric bypass

The sensitivity of the GLP-1 hormone, which is secreted by the gastrointestinal tract, can predict the metabolic efficacy of a gastric bypass. The use of a GLP1 challenge could thus function as a novel predictive biomarker for personalized treatment of type 2 diabetes and obesity.

8 Nov 2013

TSRI scientists study 3-D structure of glucagon receptor for treatment of diabetes

The study is reported on July 17, 2013, in an advance online edition of the journal Nature, alongside a British laboratory's structural study of another member of the same class of receptors-known as "class B" G protein-coupled receptors (GPCRs).

18 Jul 2013

GLP1 medications appear to protect diabetic patients from heart failure

A class of medications commonly prescribed to lower blood sugar in diabetic patients appears to protect them from developing heart failure, according to a study at Henry Ford Hospital in Detroit.

11 Mar 2013

Redpoint Bio fourth quarter revenues are $0.7 million for 2010

Redpoint Bio Corporation, a company focused on the development of healthier foods and beverages and new approaches to the treatment of diabetes and obesity, today announced financial and operational results for the quarter and year ended December 31, 2010.

5 Mar 2011

TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1b trial of ViaDor-GLP1 agonist, which is being developed for the treatment of diabetes mellitus type II.

22 Feb 2011

Oramed announces publication of GLP-1 analog formulation in Journal of Diabetes

Oramed Pharmaceuticals Inc. a developer of oral drug delivery solutions, announces a publication in the Journal of Diabetes Science and Technology's November issue describing evaluation of the company's glucagon-like peptide- (GLP-1) analog formulation (ORMD-0901) in regulating glucose excursions in animal models.

2 Dec 2010

Redpoint Bio decreases third quarter net loss to $1.8 million

9 Nov 2010

TransPharma Medical completes ViaDerm-GLP1 agonist Phase 1a trial for type II diabetes

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1a trial of ViaDerm-GLP1 agonist which is being developed for the treatment of diabetes mellitus type II.

14 Sep 2010

Redpoint Bio issued patent that covers high-throughput screening technology

Redpoint Bio Corporation, a company focused on the development of healthier foods and beverages and new approaches to the treatment of diabetes and obesity, today announced the issuance of Patent No. 7,749,730 B2 by the U.S. Patent and Trademark Office entitled "High Throughput Screening Assay for the TRPm5 Ion Channel."

28 Jul 2010

Redpoint Bio announces revenue of $1.9M for full-year 2009

29 Mar 2010

How and why weight-reducing surgery sometimes cures diabetes

95% of morbidly obese people – those with a Body Mass Index of over 40 – have Type 2 diabetes, sometimes known as maturity-onset diabetes.

5 Jun 2007

Pine nut oil boosts appetite suppressors

In the face of the growing obesity health challenge, "appetite suppressants are increasingly interesting because they work on the very simple premise of 'What you don't eat now, you won't need to lose later,'" Alexandra Einerhand, director, nutrition and toxicology-Europe at Lipid Nutrition notes.

4 Apr 2006

Severe hypoglycemia - complication of gastric bypass surgery

Physicians monitoring patients who have undergone gastric bypass surgery should be on the alert for a new, potentially dangerous hypoglycemia (low blood glucose) complication that, while rare, may require quick treatment, according to a new study

12 Oct 2005